In the first of two papers for the Macdonald-Laurier institute examining the history and impact of drug price controls in Canada, I argue for doing away with the Patented Medicine Prices Review Board and leading nations toward a more equitable sharing of the costs of pharmaceutical development. The first paper is here, and the second will be published shortly.
Intellectual Property and Innovation Law and Policy
Richard C. Owens